Clinical trials: Hypercholesterolaemia
Dyslipidemias, Hypercholesterolemia
Effect On Serum Cholesterol Of Dairy Products With Addition Of Esterified Phytosterols
Hypercholesterolemia is an important risk factor for cardiovascular disease, asociated primarily with high plasma levels of LDL lipoprotein, which in turn depend on the endogenous hepatic synthesis of cholesterol and its…
- Trial name
- ACTICOL (NCT02644109)
- Testing
- Phytosterol
- Where
- 2 sites in Chile
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- University of Chile
Hyperlipidemias
Trial of Antroquinonol in Patients With Hypercholesterolemia and Hyperlipidemia
Identified the efficacy of Antroquinonol (Hocena 50mg) in triglyceride, lipid-lowering and fatty liver.
- Trial name
- NCT02719028
- Testing
- Antroquinonol
- Where
- 6 sites in Taiwan
- Volunteers
- 120 people
- Sponsor
- Golden Biotechnology Corporation
Cardiovascular Diseases, Hypercholesterolemia
Vascular Lifestyle-Intervention and Screening in Pharmacy
The overall goal of the present project is to contribute to new knowledge about the effect of a low threshold population screening system for cardiovascular risk factors in Norway.
- Conditions
- Cardiovascular Diseases, Hypercholesterolemia, Dyslipidemia, Hypertensive Disease
- Trial name
- VISA (NCT02223793)
- Testing
- Information on high risk factor levels and lifestyle advice, No information on high risk factor levels but lifestyle advice, No information on high risk factor levels, nor lifestyle advice
- Where
- Norway
- Volunteers
- 582 people, healthy volunteers welcome
- Sponsor
- University of Oslo
Homozygous Familial Hypercholesterolemia
Gene Analysis and Treatment Optimization in Chinese Homozygous Familial Hypercholesterolemia
Identify new or novel genes which may impact on cholesterol level, and establish the relationship between those gene mutations with atherosclerosis, as well as responses to lipid-lowering drugs.
- Trial name
- NCT01878604
- Testing
- Gene analysis, Historical data of lipid-lowering drug administration, Historical data of plasma lipids, xanthoma changes
- Where
- China
- Volunteers
- 5 people
- Sponsor
- Central South University
Hypercholesterolemia
Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With High Cardiovascular Risk and Hypercholesterolemia (ODYSSEY COMBO I)
Alirocumab (SAR236553/REGN727) is a fully human monoclonal antibody that binds proprotein convertase subtilisin/kexin type 9 (PCSK9).
- Trial name
- NCT01644175
- Testing
- Alirocumab, Lipid-Modifying Therapy (LMT)
- Where
- 76 sites in United States
- Volunteers
- 316 people
- Sponsor
- Sanofi
Hypercholesterolemia
Post-marketing Surveillance of the Safety, Tolerability and Efficacy of Vytorin (Ezetimibe + Simvastatin) Tablet Among Filipino Patients (Study P05647)
This study aims to establish the safety, tolerability, and efficacy of Vytorin (R) (Ezetimibe + Simvastatin) (SCH 465981) on a select population of Filipinos with hypercholesterolemia.
- Trial name
- NCT00909389
- Testing
- Vytorin (R) (Ezetimibe + Simvastatin)
- Volunteers
- 4,748 people
- Sponsor
- Organon and Co
Lipid Metabolism Disorders
Efficacy and Safety of Fluvastatin Sodium Extended Release Tablets 80 mg Once Daily in Chinese Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia
This study is to demonstrate therapeutic comparability of Fluvastatin sodium Extended Release Tablets 80 mg QD and Fluvastatin sodium Immediate Release Capsules 40 mg BID in LDL-C lowering from baseline to week 12 (endpoint) in…
- Trial name
- NCT01551173
- Testing
- Fluvastatin sodium
- Where
- China
- Volunteers
- 436 people
- Sponsor
- Novartis Pharmaceuticals
Hyperlipidemia
Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects -2
The primary objective was to evaluate the effect of 12 weeks of subcutaneous (SC) evolocumab every 2 weeks (Q2W) and monthly (QM), compared with ezetimibe, on percent change from baseline in low-density lipoprotein cholesterol…
- Trial name
- GAUSS-2 (NCT01763905)
- Testing
- Evolocumab, Ezetimibe
- Where
- 58 sites in United States, Australia and 12 more
- Volunteers
- 307 people
- Sponsor
- Amgen
Dyslipidemia
A Study of LY2484595 in Patients With High LDL-C or Low HDL-C
The primary purpose of your participation in this study is to help answer the following research question(s) Whether LY2484595 in combination with a statin drug (atorvastatin, simvastatin or rosuvastatin; currently used to treat…
- Trial name
- NCT01105975
- Testing
- LY2484595, Atorvastatin, Simvastatin
- Where
- 59 sites in United States, Denmark and 4 more
- Volunteers
- 398 people
- Sponsor
- Eli Lilly and Company
Hypercholesterolemia, Dyslipidemia
Efficacy/Safety of Rosuvastatin+Ezetimibe in High Risk Patients With Primary Hypercholesterolemia/Mixed Dyslipidemia
The purpose of this study is to determine the non-inferiority between two different FDC (fixed-dose combination), measuring LDL-Cholesterol levels, in high risk patients with primary hypercholesterolemia or mixed dyslipidemia.
- Trial name
- LANCE (NCT01420549)
- Testing
- Rosuvastatin 10 mg + Ezetimibe 10 mg and Rosuvastatin 20 mg + Ezetimibe 10 mg, according to clinical evaluation., Simvastatin 20 mg + Ezetimibe 10 mg and Simvastatin 40 mg + Ezetimibe 10 mg, according to clinical evaluation.
- Where
- 7 sites in Brazil
- Volunteers
- 129 people
- Sponsor
- Ache Laboratorios Farmaceuticos S.A.
Chronic Kidney Disease, High Cholesterol
The Effect of Atorvastatin on Endothelial Cell Dysfunction in Chronic Kidney Disease
The purpose of this study is to see if patients with chronic kidney disease have endothelial cells that don't function properly, which is thought to be a marker for cardiovascular risk.
- Trial name
- NCT02133534
- Testing
- Atorvastatin
- Volunteers
- 1 people
- Sponsor
- Duke University
Hypercholesterolemia
A Study to Evaluate the Effectiveness of Ezetimibe/Atorvastatin 10 mg/40 mg Combination Tablet Compared to Marketed Ezetimibe 10 mg and Atorvastatin 40 mg Tablets in Participants With High Cholesterol (MK-0653C-190 AM1)
The purpose of this study is to determine whether ezetimibe/atorvastatin 10 mg/40 mg combination tablet is equivalent to the coadministration of ezetimibe 10 mg and atorvastatin 40 mg in lowering…
- Trial name
- NCT01370603
- Testing
- Atorvastatin, Ezetimibe, Ezetimibe/atorvastatin
- Volunteers
- 328 people
- Sponsor
- Organon and Co
Hypercholesterolemia, Atherosclerosis
Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) as Add-on to Ezetimibe Therapy in Patients With Elevated LDL-C (CLEAR Tranquility)
The purpose of this study is to determine if bempedoic acid (ETC-1002) added-on to ezetimibe therapy is effective and safe versus placebo in patients with elevated LDL cholesterol.
- Conditions
- Hypercholesterolemia, Atherosclerosis, Statin Adverse Reaction
- Trial name
- NCT03001076
- Testing
- Bempedoic acid, Ezetimibe
- Where
- United States
- Volunteers
- 269 people
- Sponsor
- Esperion Therapeutics, Inc.
Heterozygous Familial Hypercholesterolemia
A 52 Week Study To Assess The Use Of Bococizumab (PF-04950615; RN316) In Subjects With Heterozygous Familial Hypercholesterolemia
This is a multicenter, randomized study in subjects with heterozygous familial hypercholesterolemia receiving highly effective statins to assess the safety, efficacy and tolerability of Bococizumab (PF-04950615; RN316) to lower…
- Trial name
- SPIRE-FH (NCT01968980)
- Testing
- Bococizumab (PF-04950615;RN316)
- Where
- 88 sites in United States, Bulgaria and 9 more
- Volunteers
- 370 people
- Sponsor
- Pfizer
Primary Hypercholesterolemia, Mixed Dyslipidemia
Efficacy and Safety of Extended Release (ER) Niacin/Laropiprant When Added to Ongoing Lipid-Modifying Therapy in Patients With High Cholesterol or Abnormal Lipid Levels (MK-0524A-133)
This is a multicenter, randomized, double-blind, placebo-controlled study in participants with primary hypercholesterolemia or mixed dyslipidemia, and elevated low density lipoprotein-cholesterol (LDL-C) to assess the efficacy…
- Trial name
- NCT01274559
- Testing
- Extended-release niacin/laropiprant (ERN/LRPT)
- Volunteers
- 1,173 people
- Sponsor
- Merck Sharp & Dohme LLC
High Triglycerides, Hypercholesterolemia
Omega-3 Fatty Acids (Lovaza) for Second Generation Antipsychotic-Associated Hypertriglyceridemia
This is an open-label pilot study of omega-3 fatty acids (Lovaza) for hypertriglyceridemia in subjects who have been on an atypical (second-generation) antipsychotic medication.
- Conditions
- High Triglycerides, Hypercholesterolemia, Schizophrenia, Schizoaffective Disorder
- Trial name
- NCT00833976
- Testing
- Lovaza
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- Massachusetts General Hospital
Homozygous Familial Hypercholesterolemia
Safety, Tolerability and Efficacy of Microsomal Triglyceride Protein (MTP) Inhibitor
The primary objective of this study is to evaluate the safety and tolerability of 4 doses of lomitapide (AEGR-733; BMS-201038) given as an initial low dose and then escalated through an additional 3 dose levels over a 16-week…
- Trial name
- NCT01556906
- Testing
- Lomitapide
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Aegerion Pharmaceuticals, Inc.
Hyperlipidemia, Hypercholesterolemia
A Prospective, Open Label Comparison of Ezetimibe, Niacin, and Colestipol as Adjunct Therapy in Lipid Reduction
To compare LDL reduction compared to baseline in patients using maximum tolerated HMG CoA Reductase inhibitor (statin) therapy with adjunctive therapy with ezetimibe, colestipol, or niacin.
- Trial name
- NCT00203476
- Testing
- Niacin, Colestipol, Ezetimibe
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Tuscaloosa Research & Education Advancement Corporation
Hypercholesterolemia
A Study Comparing CoQ10 Levels While Taking 3 Different Statins
The purpose of this study is to determine if Pitavastatin lowers CoQ10 less than Atorvastatin or Rosuvastatin.
- Trial name
- SPARQ (NCT01660191)
- Testing
- Pitavastin 4mg, Atorvastatin 20mg, Rosuvastatin 5mg
- Where
- United States
- Volunteers
- 134 people
- Sponsor
- University of Kansas Medical Center
Familial Hypercholesterolemia
Atorvastatin Three Year Pediatric Study
The purpose of this study is to characterize three year descriptive growth and development (ie, height, weight, body mass index, Tanner Stage) and efficacy of cholesterol reduction in pediatric subjects with Heterozygous Familial…
- Trial name
- NCT00827606
- Testing
- atorvastatin
- Where
- 40 sites in United States, Belgium and 13 more
- Volunteers
- 272 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.